Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:45:24.645Z.
Calculation as of: 2026-10-06T22:45:24.645Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a4d4a138dd8434a7100af030d95cbc2d10a06a8c2908319c26333cf652cdf112
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$3.28M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.14M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.07M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.49M
EV/EBIT Ratio
N/A
TTM Avg
1224.32x
3Y Avg
1224.32x
5Y Avg
1224.32x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aethlon Medical, Inc. (AEMD) | $3.21M | N/A | N/A | N/A | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.25M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | N/A | N/A | N/A | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A | N/A | N/A | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $2.94M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | 1224.32x | 1224.32x | 1224.32x |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
